TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03772314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine-Dextroamphetamine
Description: Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
Study: NCT03616587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with ribociclib
Description: Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with ribociclib
Description: Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with anastrozole
Description: Part M: AZD9833 in combination with anastrozole dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with anastrozole
Description: Part N: AZD9833 in combination with anastrozole dose expansion
Study: NCT00675961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI)
Description: Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCI + Naltrexone
Description: Combination of the two previous interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
Study: NCT00280475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation therapy arm
Description: Whole brain radiation therapy arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salvage stereotactic radiosurgery arm
Description: Salvage stereotactic radiosurgery arm
Study: NCT00463151

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rebamipide
Description: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide
Description: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide
Description: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebamipide
Description: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
Study: NCT01888562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
Study: NCT04664335

Intervention type: OTHER
Intervention: questionnaire
Description: if no Reply to questionnaire, telephone interview

Intervention type: OTHER
Intervention: questionnaire
Description: if no Reply to questionnaire, telephone interview
Study: NCT00807027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated T lymphocyte(Immuncell-LC)
Description: Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109\~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)
Study: NCT01899248

Intervention type: DRUG
Intervention: Sevoflurane

Intervention type: DRUG
Intervention: Desflurane
Study: NCT02711722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally adjusted ventilatory assist
Description: Ventilation supported by NAVA~* Blood gas analysis~* Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally adjusted ventilatory assist
Description: Ventilation supported by NAVA~* Blood gas analysis~* Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally adjusted ventilatory assist
Description: Ventilation supported by NAVA~* Blood gas analysis~* Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PScli1
Description: Pressure support set by clinicians prior to inclusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PScli2
Description: Pressure support at the same level as prior to the study
Study: NCT03436121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine is a medication approved by the US Food and Drug Administration (FDA) for anesthesia, sedation, and post-surgical pain treatment. It is not approved for emergency patients complaining of pain but is often used off-label. Ketamine may be useful for acute pain management and in treatment of depressed mood. The purpose of this study is to determine whether a single low dose of ketamine can relieve pain and reduce negative mood for 2 weeks after emergency department (ED) treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
Study: NCT01235325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phylloquinone (vitamin K1)
Description: 1000 mcg phylloquinone (vitamin K1) once daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo oil capsule
Study: NCT02787538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: US-ANSWER-2 decision aid
Description: US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group (Online medication guide)
Description: Standard online medication guide.
Study: NCT04555629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Cognitive Stimulation Therapy Hong Kong
Description: A modified version of Cognitive Stimulation Therapy for people with moderate to severe dementia translated and culturally adapted for the Hong Kong Chinese population.
Study: NCT04018443

Intervention type: DIAGNOSTIC_TEST
Intervention: common carotid artery diameter measurement
Description: measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: \[(dia-mpost/dia-mpre) × 100\] - 100 \[11\].
Study: NCT00936013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: 75mg p.o Bid for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir and chinese medicinal herbs
Description: oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
Study: NCT00980707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (fluticasone)
Description: inhaled fluticasone 220 ug/bid
Study: NCT00905060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSPPC-96
Description: Autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgical Resection
Description: Patients will undergo standard surgical resection of intracranial tumor
Study: NCT03790293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Rituximab in association with low corticosteroids'therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids'therapy
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids'therapy
Description: Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
Study: NCT03654586

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sugary drink warning labels
Description: The description of each intervention appears in the descriptions of the experimental arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: The description of each intervention appears in the descriptions of the experimental arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: The description of each intervention appears in the descriptions of the experimental arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: The description of each intervention appears in the descriptions of the experimental arms.
Study: NCT03939221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infrared Lamp and Acupressure
Description: Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6 and ST36 for one minutes) for our patient for the cold limbs, pain control and constipation problems.
Study: NCT04124991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Radioembolization with Yttrium-90 Microspheres

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization
Description: Radioembolization with Yttrium-90 Microspheres
Study: NCT03195582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corsodyl
Description: following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
Study: NCT02809638

Intervention type: OTHER
Intervention: ultrasound elastography
Study: NCT03685279

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nurtured Heart Approach
Description: Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurtured Heart Approach
Description: Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
Study: NCT03302533

Intervention type: PROCEDURE
Intervention: Total elbow arthroplasty
Description: Implantation of a total elbow arthroplasty after distal humerus fracture

Intervention type: PROCEDURE
Intervention: Total elbow arthroplasty
Description: Implantation of a total elbow arthroplasty after distal humerus fracture
Study: NCT03699930

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Anodal or sham tDCS will be applied to the scalp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Anodal or sham tDCS will be applied to the scalp.
Study: NCT04534855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprilimab
Description: Treprilimab 240mg Q3W until progression or unacceptable toxicity
Study: NCT02702934

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test meal
Description: Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
Study: NCT01880515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
Study: NCT02061761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558
Description: Specified Dose on Specified Days
Study: NCT02839083

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thoracic Paravertebral group
Description: Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pecs II group
Description: Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
Study: NCT00929305

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia PL2000
Description: The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Inactive laser light
Study: NCT04542447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nuvastatic
Description: Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nuvastatic
Description: Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy
Study: NCT00597870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoluminal treament of thoracic lesions
Description: Endoluminal treament of thoracic lesions with a thoracic stent-graft
Study: NCT04243161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 50% load after MIP measurement.~The intensity of the treatment will be 50% of the PIM and PEM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The study variables PIM, PEM, FVC, PEF and EQ-5D quality of life questionnaire will be measured on the first day when patient incorporated into the seating position in the patient's bed. Reassessments will be performed every two week till patient discharge from hospital. After that patient will be assessed after 4 month and 1 year after the SCI.~SCIM III will be administered at discharge, 4 month later and 1 year after the injury.~Common clinical practice (pulmonary expansion exercises,drainage of secretions and training of inspiratory muscles) + expiratory muscle training at 30% load after MIP measurement.~The intensity of the treatment will be 30% of the PIM value (increasing the load in 2 cmH2O weekly). Three sets of 10 reps will be performed, with one total of 30 repetitions, resting 1 minute between each series.~The sessions will be held once per day, from monday to friday, during the entire hospital admission.
Study: NCT01473420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: Variable dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epogen Amgen
Description: Variable dose
Study: NCT06115577

Intervention type: DIAGNOSTIC_TEST
Intervention: endometrial tissue and peripheral blood mononuclear cells receptivity
Description: Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.

Intervention type: DIAGNOSTIC_TEST
Intervention: endometrial tissue and peripheral blood mononuclear cells receptivity
Description: Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.

Intervention type: DIAGNOSTIC_TEST
Intervention: endometrial tissue and peripheral blood mononuclear cells receptivity
Description: Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.

Intervention type: DIAGNOSTIC_TEST
Intervention: endometrial tissue and peripheral blood mononuclear cells receptivity
Description: Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
Study: NCT03626753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam 20 MG/ML
Description: given by Oral route the dose of 20mg every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam (Acupan) 20 MG/ML Injectable Solution
Description: given by intravenous route at the dose of 20mg every 6 hours.
Study: NCT03699930

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech and language therapy
Description: A trained speech pathologist will administer the speech and language therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech and language therapy
Description: A trained speech pathologist will administer the speech and language therapy.
Study: NCT03626753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, (paracetamol) 500Mg Tab
Description: 2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Acetaminophen paracetamol) IV Soln 10 MG/ML
Description: Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Piroxicam piroxan) 20 MG Oral Tablet
Description: 2 tablets of piroxicam (piroxan) administrated orally once per 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Piroxicam piroxan) 20Mg/1mL Injection
Description: 2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours.
Study: NCT03688646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intensive Nutrition Intervention
Study: NCT01904877

Intervention type: BEHAVIORAL
Intervention: Enhancing HIV testing
Description: SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
Study: NCT02860468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Description: cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.